When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Kyverna Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Naji Gehchan, M.D., MBA, as Chief ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...

"The Baylor University Black Gospel Preservation Program has an amazing team that has worked diligently ... that founded the pharmaceutical firm Eli Lilly and Co. The endowment, which is ...